136 results on '"Hua, Lingyang"'
Search Results
2. Predicting meningioma grades and pathologic marker expression via deep learning
3. The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study
4. Identification of the Key Immune Cells and Genes for the Diagnostics and Therapeutics of Meningioma
5. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk
6. Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype
7. Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord
8. Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas
9. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma
10. The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study
11. PATH-51. GENETIC CHARACTERIZATION AND MUTATIONAL PROFILING OF FORAMEN MAGNUM MENINGIOMAS: A MULTI-INSTITUTIONAL STUDY
12. CBX7 reprograms metabolic flux to protect against meningioma progression by modulating the USP44/c-MYC/LDHA axis
13. A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma
14. Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center
15. Angiomatous Meningiomas Have a Very Benign Outcome Despite Frequent Peritumoral Edema at Onset
16. Frequent NF2 mutations contribute to spinal location predominance and worse outcomes in psammomatous meningiomas
17. Prognostic Factors in Patients with Primary Hemangiopericytomas of the Central Nervous System: A Series of 103 Cases at a Single Institution
18. Ash1L Ameliorates Psoriasis via Limiting Neuronal Activity-Dependent Release of miR-let-7b
19. Favorable Long-Term Outcomes of Chordoid Meningioma Compared With the Other WHO Grade 2 Meningioma Subtypes
20. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk
21. Progesterone receptor expression and prediction of benefits of adjuvant radiotherapy in de novo atypical meningiomas after gross-total resection
22. SURG-11. AKT1 E17K AND NF2 MUTATIONS DOMINATE SPINAL MENINGIOMAS WHO GRADE 1 AND PRESENT DISTINCT TUMOR FEATURES
23. Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma
24. Application of MRI-Based Radiomics in Preoperative Prediction of NF2 Alteration in Intracranial Meningiomas
25. AKT1E17K- und NF2-Mutationen sind die Hauptereignisse bei spinalen Meningeomen und sind mit unterschiedlichen Tumormerkmalen assoziiert
26. LncRNA-IMAT1 Promotes Invasion of Meningiomas by Suppressing KLF4/hsa-miR22-3p/Snai1 Pathway
27. Regulation and roles of RNA modifications in aging‐related diseases
28. Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype
29. IRAK4 exacerbates traumatic brain injury via activation of TAK1 signaling pathway
30. Favorable Long-Term Outcomes of Chordoid Meningioma Compared With the Other WHO Grade 2 Meningioma Subtypes.
31. miR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells
32. Microcystic Meningioma Has A Worse Outcome Than Other WHO Grade 1 Subtypes
33. m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes
34. TERT Alterations Predict Tumor Progression in De Novo High-Grade Meningiomas Following Adjuvant Radiotherapy
35. Molecular diagnosis and treatment of meningiomas: an expert consensus (2022).
36. MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma
37. Letter to the Editor Regarding “Stereotactic Radiosurgery for Atypical and Anaplastic Meningiomas”
38. Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma
39. High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma
40. Long-term outcomes of multimodality management for parasagittal meningiomas
41. The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations
42. m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes.
43. The Diagnostic Value Of Using 18F-Fluorodeoxyglucose Positron Emission Tomography To Differentiate Between Low- And High-Grade Meningioma
44. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application
45. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma
46. Intra-operative motor function preservation for resection of primary motor cortex meningioma
47. EXTH-20. HISTONE DEACETYLASE INHIBITOR ENHANCES ONCOLYTIC HERPES SIMPLEX VIRUS THERAPY FOR MALIGNANT MENINGIOMA
48. Clivus Inflammatory Pseudotumor Associated with Immunoglobulin G4-Related Disease
49. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution
50. β1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.